B Braun receives FDA approval for Nutrilipid 20%
An intravenous fat emulsion approved for adult and pediatric patients
B Braun Medical, a leader in infusion therapy and pain management, has received US Food and Drug Administration (FDA) approval of Nutrilipid 20% (I.V. fat emulsion) for parenteral nutrition therapy in adult and pediatric patients.
Nutrilipid 20% is indicated as a source of calories and essential fatty acids for parenteral nutrition and as a source of essential fatty acids when a deficiency occurs when oral or enteral nutrition is not possible, insufficient, or contraindicated. The approval of Nutrilipid 20% will help alleviate the short supply of lipid emulsion products the US has seen over the past two years. It will be available in flexible containers that are not made with DEHP, PVC or natural rubber latex. Launch plans are expected soon.
'We are very pleased that the FDA has granted approval for Nutrilipid 20%,' said Rick Williamson, Vice President of Pharmaceutical Marketing. 'Through our state-of-the-art production facility, we are committed to providing quality clinical nutrition products so that patients have access to parenteral nutrition they often critically need.
'B.Braun continues to expand upon its customised approach to clinical nutrition and compounding to meet the needs of patients along the entire clinical pathway.'